This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Fleishman Hillard
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies creates a new Sirtex SIR-Spheres microspheres Hub iPad app in addition to redesigned company website
Woburn, MA (PRWEB) December 12, 2012
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today the availability of a portfolio of digital resources, including a new global website, designed to provide easy access to SIR-Spheres® microspheres educational materials. The new Sirtex website offers location-based, customized information pertinent to physicians, patients and caregivers in an easy-to-navigate format. The site also includes expanded product and disease state content, and the latest SIR-Spheres microspheres clinical study information. Sirtex’s SIR-Spheres microspheres are the only fully FDA-approved microsphere radiation therapy for the treatment of colorectal liver metastases.
“We launched this initiative to further our goal of educating physicians, patients, and caregivers about SIR-Spheres microspheres,” said Mike Mangano, President of Sirtex Medical Inc. “With the increased use of electronic channels as a source of medical information, we wanted to make it easy for people battling cancer to access important information through some of the most commonly utilized methods today.”
In addition to the redesigned company website, Sirtex created a new Sirtex SIR-Spheres microspheres Hub iPad app which is available for download from the Apple iTunes store. This educational tool provides an assortment of procedural information for healthcare professionals and their patients including an animated procedure overview, Mode of Action (MOA) video, patient education materials, key clinical publications as well as disease state and clinical data presentations.
Additionally, through its Facebook Fan Page, Sirtex continues to build a community of patients, caregivers, advocacy groups, and physicians. The Facebook page offers resources, updates, information, and case studies at the click of a button.
Physicians and patients are also encouraged to check out the latest materials available through the Sirtex SlideShare account. With SlideShare, Sirtex is able to share videos and presentations that provide additional background content and information about SIR-Spheres microspheres.
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark), and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 600 treatment centers, over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide.
For more information, visit http://www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10229011.htm
635 W. 7th Street